Cogent Biosciences (COGT) Stock Price

Cogent Biosciences Inc is primarily active in the biotechnology industry.

The main competitors of Cogent Biosciences Inc in the market include large pharmaceutical companies such as Amgen, Inc., Gilead Sciences, Inc., and AbbVie Inc. These companies operate in the same biotechnology industry, striving to discover and develop innovative therapies for various diseases. Cogent Biosciences Inc competes with these industry leaders, focusing on advancing its proprietary precision medicine platform to target rare and genetically defined diseases. By leveraging its expertise and strategic collaborations, Cogent Biosciences Inc aims to differentiate itself and create valuable solutions in the highly competitive biotech market.

Cogent Biosciences Inc is a pharmaceutical company headquartered in Cambridge, Massachusetts. Established in 2015, the company focuses on developing precision therapies for genetically defined diseases. Cogent Biosciences primarily concentrates on discovering and developing drugs that target genetically driven forms of cancer. By leveraging its expertise in precision medicine and computational biology, the company aims to advance innovative treatments for patients in need. Cogent Biosciences Inc has established collaborations with leading academic institutions and industry partners to accelerate the development of its therapeutic candidates. With its commitment to scientific excellence, Cogent Biosciences Inc strives to transform the lives of patients by delivering breakthrough therapies for genetically driven diseases.

Some significant milestones achieved by Cogent Biosciences Inc include the successful completion of clinical trials for their lead drug candidate, CGT9486, which showed promising results in treating certain cancer types. The company also secured collaborations with renowned research institutions and pharmaceutical companies to further develop their pipeline. Cogent Biosciences Inc received FDA Fast Track designation for CGT9486, recognizing its potential as a breakthrough therapy. Furthermore, the company successfully raised funding through public offerings to support their research and development efforts. These achievements highlight Cogent Biosciences Inc's commitment to advancing innovative treatments in the field of biotechnology and their dedication to improving patient outcomes.

Cogent Biosciences Inc is primarily present in the United States.

Cogent Biosciences Inc represents a commitment to advancing the treatment options for patients with genetically-driven diseases. The company focuses on developing precision medicines that target the underlying causes of these diseases. Cogent Biosciences is driven by a patient-centric approach and values scientific innovation, collaboration, and patient advocacy. The company strives to make a meaningful impact on patients' lives by translating scientific discoveries into effective therapies. With its dedication to improving patient outcomes, Cogent Biosciences Inc aims to shape the future of precision medicine and contribute to the advancement of healthcare.

Analysts currently set an average price target of 48.40 USD for the Cogent Biosciences stock (median: 52.00 USD), implying +60.6 % versus the latest price. The consensus is based on 18 analyst ratings.

Cogent Biosciences Analyst Price Targets 2026

18 analysts currently rate the Cogent Biosciences stock: 16 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Cogent Biosciences to generate revenue of 5.98 M USD and earnings per share of -3.41 USD.

Cogent Biosciences Analyst Price Targets 2026

Converted at the current exchange rate, the Cogent Biosciences share trades at 26.91 EUR (30.14 USD).

The Cogent Biosciences share (COGT) is listed on 1 stock exchanges, including: NASDAQ (COGT).

Cogent Biosciences Inc is a company specializing in the development of highly effective therapies for patients with serious immune system diseases and cancer. The company is headquartered in Cambridge, Massachusetts and was founded in 2015. Cogent Biosciences' business model is based on the development of therapies targeting critical signaling molecules in cellular signaling pathways that are critical in various types of cancer and autoimmune diseases. Cogent Biosciences plans to address the unmet medical need in these areas by developing innovative novel treatments using the unconventional approach of Doer-to-Drug Discovery. The company's research programs focus on identifying critical cellular signaling pathways that must be regulated in both cancer and autoimmune diseases. Cogent Biosciences has a proprietary screening platform that allows the company to quickly identify "druggable" targets and develop novel therapeutic agents. The company's platform is specifically designed to identify novel chemical compounds targeting cellular signaling pathways associated with cancer and autoimmune diseases. Cogent Biosciences relies on a partnering strategy that leverages the expertise and resources of large pharmaceutical companies to accelerate its clinical development programs. Cogent Biosciences focuses on clinical development programs in two key areas: cancer and autoimmune diseases. The focus of Cogent Biosciences' cancer programs is on the discovery of novel signaling pathways dysregulated in various tumor types. The company is working to develop effective clinical therapies targeting these unconventional signaling pathways. In the company's autoimmune research, Cogent Biosciences focuses on modulating immune-suppressed patient pathways and developing new innovative therapy approaches aimed at increased efficacy. Cogent Biosciences recently completed its Phase 1b study of the orally administered clinical candidate CGT9486, a first-in-class inhibitor targeting the BTK signaling target, which plays a significant role in many solid tumors. Also currently underway is a Phase 1b/2a study investigating the first-in-class inhibitor CGT378 in patients with EGFR cancer tumors. Cogent Biosciences is one of the newest pharmaceutical companies in the growth market and has shown successful investment in a few years with investors supporting the company. Cogent Biosciences expects its Doer-to-Drug Discovery approach to contribute to the long-term development of therapies that address the unmet medical need in both cancer and rheumatoid arthritis or lupus.

The expected revenue of Cogent Biosciences is 5.98 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Cogent Biosciences is -230.28 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cogent Biosciences is currently -8.85. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cogent Biosciences stock.

The price-to-sales ratio (P/S) of Cogent Biosciences is currently 340.64. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cogent Biosciences stock.

The Eulerpool Quality Score for Cogent Biosciences is 2/10.

The ISIN of Cogent Biosciences is US19240Q2012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Cogent Biosciences is A2QJAY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Cogent Biosciences is COGT. The ticker symbol is used to trade Cogent Biosciences shares on the stock exchange.